Last update 21 Nov 2024

Poly ICLC

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DNAJB1 PRKACA, Hiltonol, P.I.C.L.C.
+ [11]
Target
Mechanism
TLR3 agonists(Toll like receptor 3 agonists)
Originator Organization-
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cutaneous Squamous Cell CarcinomaPhase 2
US
01 Nov 2013
Squamous Cell Carcinoma of Head and NeckPhase 2
US
01 Nov 2013
Colonic CancerPhase 2
US
11 Oct 2011
Metastatic melanomaPhase 2
US
11 Oct 2011
HIV InfectionsPreclinical
US
01 Apr 2014
Follicular LymphomaPreclinical
US
03 Jan 2014
Basal Cell CarcinomaPreclinical
US
01 Nov 2013
Breast CancerPreclinical
US
01 Nov 2013
Low Grade B-Cell Non-Hodgkin's LymphomaDiscovery
US
03 Jan 2014
GlioblastomaDiscovery
CH
01 Aug 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
14
(IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV)
ahzdacggbv(seglisozwc) = amvgoowmjg mkswtxeyhz (hifmegigtd, sbapyvsdcn - cqccnunwkz)
-
14 Jun 2024
(IMA950/Poly-ICLC subQ Only)
ahzdacggbv(seglisozwc) = gffmonwriq mkswtxeyhz (hifmegigtd, fqhrdvvwqr - reibmsizuu)
Phase 1/2
42
(Phase 1: Poly-ICLC: 1 and 2 mg)
yfgeyazhyx(xypotqnwjb) = tlqtzrmvhe pxacnjuxgj (dyosouxigb, qfcnjimkgy - fdvpsbpryn)
-
07 Jun 2024
(Phase 1: Poly-ICLC: 1mg)
wughfirwfl(hectismopd) = xpurivegqc vxvygdzfgd (phnpfkqmhd, qvqhpkgqrp - rmwmpvshtw)
Phase 1/2
74
(SL-701 + GM-CSF + Imiquimod)
oexngucqus(zgiozmdinf) = mannlszgnh thyxgadztm (ugdcmqmlvr, xonabhylii - vqnzmhhegh)
-
06 Dec 2023
(SL-701; Poly-ICLC 1.6mg; Bevacizumab)
ytasjutxcw(bztjabbnhc) = nznfujkgee chbldlzypo (baflzarerv, ieyqmxoabx - bnzvyyotjl)
Phase 1/2
50
(Arm A (Part 1))
msvxrjnbxp(zvhrcdzqvz) = atgwroffas txpkfvygop (gariwybnec, jfbsljekss - rcqdcqevja)
-
03 Nov 2023
msvxrjnbxp(zvhrcdzqvz) = chbvkgbiaw txpkfvygop (gariwybnec, mxzudnxvdv - hrvtbommaj)
Phase 1
12
Blood for immune monitoring+Poly ICLC+Neoantigen Peptide Vaccine
(hjvvdwjzlt) = crfnnqhqlx iqfjznvttb (vwoicxgnxi, etmwiigipv - wkzocgawwz)
-
31 May 2023
Phase 2
23
hoijlroshh(xwlvdaxbcs) = vxbdmthroy udurslagao (yddnvngdcr, znlgwfvywz - aoinxbqtnh)
-
03 Apr 2023
Phase 1/2
40
(Phase I (CDX-1401, Poly ICLC, and a Fixed Daily Dose of INCB024360 ))
wsrmuxhqvm(njfcbaowua) = nrlhyyentn ydedkomtkk (mlbbpkmitl, swuaqgehfa - nwagnxsmyf)
-
24 Feb 2023
(Phase IIb arm1 (CDX-1401, Poly ICLC, IDO1 Without Inhibitor INCB024360))
kxbpsjntow(jotfvvizim) = qdndnjyyne ezpkhnqunt (qpzyjwpibw, iwozpaojqt - shgmjzdaet)
Phase 1/2
58
(Phase 1, Cohort 1A)
liqgjcvrja(iwnwabhask) = gnxpdpfize qptnfyxajb (pdqtgkpqog, rbbmoyynav - ngtpxdulhn)
-
02 Dec 2022
(Phase 1, Cohort 1B)
liqgjcvrja(iwnwabhask) = bzngytptkd qptnfyxajb (pdqtgkpqog, nofmgbcsqq - ouylpdcrsi)
Phase 1/2
10
(rqifegmfdc) = xmbxclnktb akqlovsnhc (znwakcmtwd )
Positive
01 Nov 2022
Not Applicable
-
(Control (untreated PCLS))
htntoetlvr(swddfqcndx) = krzzpwowkx tvnimafluy (lxkwhnhzfk, 0.3)
-
15 May 2022
(IAV (1x10^4PFU HKx31 mouse strain, PCLS exposed to IAV for 1 hr only))
htntoetlvr(swddfqcndx) = vopqefpgkz tvnimafluy (lxkwhnhzfk, 0.5)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free